Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Avoid Microsaic Systems (MSYS) by Steve Moore in ShareProphets
- Avoid Aptamer Group (APTA) by Steve Moore in ShareProphets
- Avoid Transense Technologies (TRT) by Steve Moore in ShareProphets
- Outperform Linde (0M2B) by Bernstein
- Avoid Boohoo Group (BOO) by Steve Moore in ShareProphets
- Watch Raspberry PI Holdings (RPI) by Edward Sheldon in The Motley Fool
- Buy Antofagasta (ANTO) by Bank of America
- Outperform Relx plc (REL) by ODDO BHF
- Outperform Chesnara (CSN) by RBC Capital
- Buy Yellow Cake (YCA) by Berenberg
- Outperform NextEnergy Solar Fund Limited Red (NESF) by RBC Capital
- Buy Applied Nutrition (APN) by Deutsche Bank
- Neutral Legal & General Group (LGEN) by Exane
- Hold Unilever (ULVR) by Kepler Cheuvreux
- Hold Unilever (ULVR) by Berenberg
- Neutral NATWEST GROUP (NWG) by Goldman Sachs
- Buy Antofagasta (ANTO) by Goldman Sachs
- Overweight Molten Ventures (GROW) by Barclays
- Buy Melrose Industries (MRO) by Citi
- Buy AstraZeneca (AZN) by Berenberg
AstraZeneca (AZN) Share Price
Health Care Sector
NOTE: This is based on 1,259 open tips for AstraZeneca (AZN)
| Latest Bid : 15,610.00p | Latest Ask : 15,614.00p |
| High Today : 15,730.00p | Low Today : 15,482.24p |
| This Years High : 15,730.00p | This Years Low : 9,667.00p |
| Volume : 822,897 | MKT Cap : £240901M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
AstraZeneca (AZN) Overview
A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.AstraZeneca (AZN) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Ben McPoland | Premium Only | 2024-11-12 14:20:00 12/11/2024 | 56.66% |
| Overweight | JP Morgan | Premium Only | 2024-11-07 18:00:00 07/11/2024 | 42.29% |
| Buy | Shore Capital | Premium Only | 2024-11-07 15:46:00 07/11/2024 | 59.95% |
| Hold | Deutsche Bank | Premium Only | 2024-11-06 07:17:00 06/11/2024 | 22.40% |
| Buy | Ben McPoland | Premium Only | 2024-11-04 11:45:00 04/11/2024 | 39.69% |
AstraZeneca (AZN) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 15,610.00p | Latest Ask : 15,614.00p |
| High Today : 15,730.00p | Low Today : 15,482.24p |
| This Years High : 15,730.00p | This Years Low : 9,667.00p |
| Volume : 822,897 | MKT Cap : £240901M |
AstraZeneca Overview
A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest AstraZeneca Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Ben McPoland | Premium Only | 2024-11-12 14:20:00 12/11/2024 | 56.66% |
| Overweight | JP Morgan | Premium Only | 2024-11-07 18:00:00 07/11/2024 | 42.29% |
| Buy | Shore Capital | Premium Only | 2024-11-07 15:46:00 07/11/2024 | 59.95% |
| Hold | Deutsche Bank | Premium Only | 2024-11-06 07:17:00 06/11/2024 | 22.40% |
| Buy | Ben McPoland | Premium Only | 2024-11-04 11:45:00 04/11/2024 | 39.69% |